Peter Lynch fit · Growth at a reasonable price (GARP)
Is CytomX Therapeutics, Inc. (CTMX) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria — growth too low or price too high.
15/100
FNão encaixa
2/6 critérios atendidos
Os critérios de Peter Lynch, aplicados a CTMX
PEG ≤ 1.0
chave—
EPS CAGR ≥ 15%
chave0.0%
Revenue CAGR ≥ 10%
-26.8%
Net margin > 0
24.7%
Como CTMX pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$969.17M
P/L (TTM)
14.2x
ROIC (TTM)
62.2%
Margem bruta
100.0%
Perguntas frequentes
What is CTMX's Peter Lynch fit score?
CTMX scores 15/100 on our Peter Lynch fit engine — grade F. Does not fit Lynch's GARP criteria — growth too low or price too high.
Does Peter Lynch actually own CTMX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends CTMX.
How often is this score updated?
CTMX's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Peter Lynch possua ou recomende CTMX pessoalmente.